
Kadmus Pharmaceuticals Inc (AKA: Kadmus Inc) Profile last edited on: 8/22/07
CAGE:
UEI:
Business Identifier: NO Business Identifier is currently available for this company. Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 45
County: Orange
Congr. District: 45
County: Orange
Public Profile
Kadmus Pharmaceuticals Inc commercially exploits endocannabinoid pathways to develop innovative therapeutics. Endocannabinoids are naturally occurring signaling molecules whose functions include regulating pain and body weight. Through licensing activity, development partnerships and internal discovery programs, Kadmus Pharmaceuticals is building a portfolio of compounds with activity against a range of disorders of the central nervous system and metabolic disorders, including neuropathic pain and obesity
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
10-14Revenue Range
1M-1.5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
1-4Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2005 | 1 | NIH | $100,000 | |
Project Title: Oleylethanolamide derivatives as anti-obesity agents | ||||
2001 | 1 | NIH | $127,231 | |
Project Title: Identifying Ligands For A Novel Gabaa Receptor Subtype |
Key People / Management
Patrick Walsh -- President
Kelvin W Gee
Kelvin W Gee
Company News
There are no news available.